Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights

Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma

(2019) Gangyang Wang et al.   INTERNATIONAL JOURNAL OF CANCER

ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer

(2019) Iris C. Salaroglio et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

RB1 deletion in RB-pathway disrupted cells results in DNA damage and cancer progression.

(2019) Aren E. Marshall et al.   MOLECULAR AND CELLULAR BIOLOGY

Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment

(2019) Yidi Qu et al.   Molecular Cancer

Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations

(2019) Yoshiyuki Suehara et al.   CLINICAL CANCER RESEARCH

The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

(2019) Razelle Kurzrock et al.   CLINICAL CANCER RESEARCH

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

(2019) Lara E. Davis et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

(2019) A. Le Cesne et al.   EUROPEAN JOURNAL OF CANCER

Flip the coin: IL-7 and IL-7R in health and disease

(2019) João T. Barata et al.   NATURE IMMUNOLOGY

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

(2018) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting tumour microenvironment by tyrosine kinase inhibitor

(2018) Hor-Yue Tan et al.   Molecular Cancer

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment

(2018) M. Fioramonti et al.   Scientific Reports

Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer

(2018) Lorenzo Stramucci et al.   Cancers

Response to Pazopanib in Patients With Relapsed Osteosarcoma

(2018) Kunal R. Elete et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

(2018) Florence Duffaud et al.   LANCET ONCOLOGY

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting protein kinases to reverse multidrug resistance in sarcoma

(2016) Hua Chen et al.   CANCER TREATMENT REVIEWS

MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression

(2016) Hugo W. Huth et al.   CELLULAR SIGNALLING

EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation

(2016) Yuho Hamaoka et al.   CELLULAR SIGNALLING

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia

(2016) K Canté-Barrett et al.   LEUKEMIA

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

(2015) Giovanni Grignani et al.   LANCET ONCOLOGY

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

(2015) A. N. Hata et al.   Cancer Discovery

RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy

(2015) Paola Indovina et al.   Oncotarget

Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives

(2014) Emmy D.G. Fleuren et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Pazopanib and HDAC inhibitors interact to kill sarcoma cells

(2014) Seyedmehrad Tavallai et al.   CANCER BIOLOGY & THERAPY

MKK6 is Upregulated in Human Esophageal, Stomach, and Colon Cancers

(2014) Arif Ali Parray et al.   CANCER INVESTIGATION

EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties

(2014) H Miao et al.   ONCOGENE

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models

(2013) Y. Pignochino et al.   CLINICAL CANCER RESEARCH

A Review of Targeted Therapies Evaluated by the Pediatric Preclinical Testing Program for Osteosarcoma

(2013) Valerie B. Sampson et al.   Frontiers in Oncology

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells

(2012) T J Collard et al.   Cell Death & Disease

Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines

(2012) A N Rettew et al.   Oncogenesis

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

(2011) G. Grignani et al.   ANNALS OF ONCOLOGY

Multiple Stress Signals Activate Mutant p53 In Vivo

(2011) Y.-A. Suh et al.   CANCER RESEARCH

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

(2011) Priscila P Zenatti et al.   NATURE GENETICS

De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway

(2010) Raphaela Fritsche-Guenther et al.   HISTOPATHOLOGY

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

(2009) Ymera Pignochino et al.   Molecular Cancer

The Structure of the MAP2K MEK6 Reveals an Autoinhibitory Dimer

(2009) Xiaoshan Min et al.   STRUCTURE

Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage

(2008) S. D. Berman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA